Contents

Experimental Studies


A Clinically Relevant, Syngeneic Model of Spontaneous, Highly Metastatic B16 Mouse Melanoma. V. BOBEK, K. KOLOSTOVA, D. PINTEROVA, G. KACPRZAK, J. ADAMI, J. KOLODZIEJ, M. BOUBELIK, M. KUBECOVA, R.M. HOFFMAN (Prague, Czech Republic; Wroclaw, Poland; San Diego, CA, USA) ........................................................................................................................................................................... 4799

Expression of Anti-apoptosis Genes Determines the Response of Adrenal Cancer to Apoptosis-inducing Chemotherapy. D.E. SCHTEINGART, R. BENITEZ, C. BRADFORD, A. NARAYAN, S. WANG (Ann Arbor, MI, USA) ........................................................................................................................................................................................................................................ 4805

Aberrant Methylation of Heparan Sulfate Glucosamine 3-O-Sulfotransferase 2 Genes as a Biomarker in Colorectal Cancer. Y. TOKUYAMA, T. TAKAHASHI, N. OKUMURA, K. NONAKA, Y. KAWAGUCHI, K. YAMAGUCHI, S. OSADA, A. AZDAR, K. YOSHIDA (Gifu, Japan; Dallas, TX, USA) ....................... 4811

Inhibition of L-type Amino Acid Transporter 1 Has Antitumor Activity in Non-small Cell Lung Cancer. H. IMAI, K. KAIRA, N. ORIUCHI, K. SHIMIZU, H. TOMINAGA, N. YANAGITANI, N. SUNAGA, T. ISHIZUKA, S. NAGAMORI, K. PROMCHAN, T. NAKAJIMA, N. YAMAMOTO, M. MORI, Y. KANAI (Gunma; Osaka; Shizuoka, Japan) .......................................................................................................................................................................................... 4819

Contents continued on the back cover
ANTICANCER RESEARCH
International Journal of Cancer Research and Treatment

Editorial Board

B. B. AGGARWAL, Houston, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
R. C. BAST, Houston, TX, USA
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicêtre, France
Y. BECKER, Jerusalem, Israel
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
D. D. BIGNER, Durham, NC, USA
A. BÖCKING, Düsseldorf, Germany
G. BONADONNA, Milan, Italy
F. T. BOSSMAN, Lausanne, Switzerland
G. BROICH, Milan, Italy
J. M. BROWN, Stanford, CA, USA
O. S. BRULAND, Oslo, Norway
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
I. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Tachung, Taiwan, ROC
E. DE CLERCQ, Leuven, Belgium
W. DE LOECKER, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
W. EBERT, Heidelberg, Germany
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Cleveland, OH, USA
A. F. GAZDAR, Dallas, TX, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCHE, Freiburg, Germany
R. H. GOLDFARB, Princeton, NJ, USA
J. W. GORROD, Colchester, Essex, UK
S. HAMMARSTRÖM, Umeå, Sweden
I. HART, London, UK
I. HELLSTRÖM, Seattle, WA, USA
L. HELSON, Valhalla, NY, USA
R. R. HERBERMAN, Pittsburgh, PA, USA
R. M. HOFTAN, San Diego, CA, USA
C. G. IOANNIDES, Houston, TX, USA
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSON, Oslo, Norway
B. KAINA, Mainz, Germany
B. K. KEPPLER, Vienna, Austria
D. G. KIEBACK, Dresden, Germany
R. KLAPDOR, Hamburg, Germany
U. R. KLEEBERG, Hamburg, Germany
P. KLEHUES, Zurich, Switzerland
E. KLEIN, Stockholm, Sweden
S. VON KLEIST, Freiburg, Germany
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
D. W. KUFE, Boston, MA, USA
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Bergen, Norway
M. KUIROKI, Fukuoka, Japan
O. D. LAERUM, Bergen, Norway
F. J. LEJUENE, Lausanne, Switzerland
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
H. T. LYNCH, Omaha, NE, USA
J. MARIECAUX, Strasbourg, France
J. MARK, Skovlunde, Denmark
J. F. MARSHALL, London, UK
D. MEDINA, Houston, TX, USA
S. MITRA, Galveston, TX, USA
M. MUELLER, Heidelberg, Germany
F. M. MUGGIA, New York, NY, USA
M. J. MURPHY, Jr., Dayton, OH, USA
R. NARAYAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
J. F. NOVAK, Lewisburg, PA, USA
S. PATHAK, Houston, TX, USA
S. PESTKA, Piscataway, NJ, USA
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATOSOUCAS, Norfolk, VA, USA
F. PODOL, Rome, Italy
A. POLLIACK, Jerusalem, Israel
M. F. RAJEWJSKY, Essen, Germany
G. REBEL, Strasbourg, France
M. RIGAUD, Limoges, France
U. RINGROß, Stockholm, Sweden
M. ROSSELI, Rome, Italy
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
G.-I. SOMA, Tokushima, Japan
G. S. STEIN, Worcester, MA, USA
T. STIGBRAND, Umeå, Sweden
D. TARIN, La Jolla, CA, USA
T. M. THEOPHANIDES, Athens, Greece
B. TOYH, Omaha, NE, USA
P. M. ÜBELAND, Bergen, Norway
P. T. VIJHOK, Oulu, Finland
M. VOLM, Heidelberg, Germany
G. WEBER, Indianapolis, IN, USA
B. WESTERNMARK, Uppsala, Sweden
Z. ZUMOFF, New York, NY, USA
J. G. DELINASSIOS, Athens, Greece
Managing Editor: editor@iiar-anticancer.org
ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTI CANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research.
For more information about ANTI CANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: www.iiar-anticancer.org
Publication Data: ANTI CANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume.
Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.
Annual Subscription Rates 2010 per volume: Institutional subscription Euro 1,650.00 - online; Euro 1,670.00 - print & online. Personal subscription Euro 780.00 - online; Euro 800.00 - print; Euro 830 - print & online. Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-29, 1981-2009) are available at 50% discount on the above rates.
Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece, and should be sent to the Editorial Office.
Advertising: All correspondence and rate requests should be addressed to the Editorial Office.
Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.
Articles in Anticancer Research are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Pennsylvania Biochemical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, Geobase, EMBiology, Elsevier Biobase, Fluiddex, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RS Inc., PASCAL-CNRS, Innpharma, Reactions (Dataster, IRIS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, Biobase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubHub, Sociedad Iberoamericana de Información Científica (SIRC) Data Bases. Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTI CANCER RESEARCH, provided that the base fee of $2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 22 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2010 $2.00 +0.40.
The Editors and Publishers of Anticancer Research accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.
Copyright © 2010, International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Printed by Entypo, Athens, Greece
Printed on acid-free paper.
New Nanoscale Human Angiogenesis Assay

Top: Optical image of highly uniform angiogenesis antibody features in one nanoscale sub-array. Bottom: Fluorescent image showing ultrasensitive Nanoink assay results using 111 pg/ml of recombinant human antigen.

Easily Detect Low-Abundance Proteins

Until now, detecting low-abundance angiogenesis proteins has been difficult. Nanoink’s revolutionary nanoarray technology overcomes the hurdles of conventional platforms, giving you assay sensitivity in the 100 femtograms/ml range. With the nanoscale Human Angiogenesis Assay, you can simultaneously evaluate ANG, EGF, FGF, G-CSF, HGF, IL8, Leptin, PIGF, VEGF, and HB-EGF within 6 hours. And the ultra low sample requirements of this miniaturized immunoassay decrease reagent costs and conserve precious sample.

Experience the power of nanoscale. Take advantage of the Human Angiogenesis Assay special introductory price of $250 now.

Find out more at: www.nanoink.net/nanobio | 847-679-3432.
The Official Journal of the European Association for Predictive, Preventive and Personalised Medicine

The EPMA Journal

International Reviews in Predictive, Preventive and Personalised Medicine

Editor-in-Chief: Olga Golubnitschaja, University of Bonn, Bonn, Germany.

The EPMA Journal was created by the European Association for Predictive, Preventive & Personalised Medicine to provide an intelligent overview of top-level scientific developments in Laboratory medicine and potential practical applications. These can potentially improve current healthcare systems around the world, using a patient-personalised approach to shift from curative to predictive and preventive paradigms in personalised patient treatment.

The journal is designed to highlight worldwide progress in emerging discipline of Predictive, Preventive & Personalised Medicine. For this purpose, the journal provides up-to-the-minute updates on innovative predictive diagnostic technologies, targeted preventive measures and individualised therapeutic approaches in prevention and treatment of common human pathologies.

The editors strongly encourage the submission of papers relating to interdisciplinary approaches. Your research can be submitted quickly and easily through our state-of-the-art submission and peer-review system, Editorial Manager, allowing faster publication of articles. Please go to www.editorialmanager.com/epma to submit your research.
Experimental Studies